Univadis COVID-19 Weekly Overview 3 July

  • Ben Gallarda
  • Univadis Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Due to the rapidly changing nature of the COVID-19 pandemic, we at Univadis would like to share with you the most impactful and clinically relevant articles across our network from the past week.

Some of these articles are only published in local languages, but we’ve tried to summarize the key points for you below and link to the original source of each article in case you’d like to read more, with languages other than English noted in brackets.

This is a snapshot of emerging best-practices during a rapidly evolving pandemic. Any and all information currently available related to COVID-19 is subject to change as more details become available. Some of the information below may also be contradicted by local or global health authorities. You can find all of the most up-to-date COVID-19 coverage on your local Univadis site or smartphone application.

We hope this information will be useful to your ongoing medical care for all patients, whether directly involved with COVID-19 or not.

  1. Work by two European groups [German] evaluating 40 international studies has concluded that while antibody tests for SARS-CoV-2 can detect past infection, they are not yet accurate enough to demonstrate immunity or non-infectivity.
  2. Germany’s Federal Institute for Risk Assessment (BfR) has reported high levels of use of the country’s “BfR-Corona-Monitors” [German] application. 28% of over-14-year-year olds report using it, and 40% of under-40-year-olds do likewise. Uptake among the elderly (>60 years), who are at higher risk, is lower, at 19%.
  3. A new Italian report in Nature demonstrates a new assessment of early transmission dynamics in the Vo’ municipality. A researcher involved had initially suspected asymptomatic, and thus more widespread transmission of the disease, in contrast to initial WHO assessments.
  4. French Academy of Medicine [French] is warning physicians not to ignore less common symptoms of COVID-19, including neurological, skin, GI and metabolic conditions. The Academy reminds healthcare works to prescribe testing if there is even the slightest suspicion of COVID-19.
  5. Spain’s Minister of Science and Innovation, Pedro Duque made a presentation on the 12 different vaccines being currently developed in the country and the various collaborations between research groups to carry out this work. Human testing on these vaccines is expected to begin in December.
  6. The UK’s NICE has conducted a rapid evidence review concluding that Vitamin D is not effective in preventing or reducing the severity of COVID-19. The review was based on 5 observational studies, and further analyses with more incoming data are being conducted.